Evidence map›Paper›PMID 39654615›Full record

ArticleFrontiers in pharmacology2024

Siqi Yang, Jinshuai Lan, Zhe Li, Ming Li, Ya Wu, Liyan Sun, Tong Zhang, Yue Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siqi Yang *School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jinshuai Lan *School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhe LiSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ming LiSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ya WuSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Liyan SunSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Tong ZhangSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yue DingSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aims to improve the solubility and the toxicity of Bufonis venenum, and finally enhance the therapeutic outcomes of hepatocellular carcinoma (HCC). Methods: The cholesterol-free liposomes simultaneously encapsulate bufadienolides and indolealkylamines (Non-Cholesterol-Bufonis Venenum Extract-Liposome, Non-Chol-BVE-LP) was prepared by the thin-film evaporation technique. Results: The liposomes showed good size distribution, encapsulation efficiency drug loading capacity and slower drug release. Non-Chol-BVE-LP had higher cytotoxicity on HepG2 cells and induced more apoptosis on HepG2 Cells compared with BVE. In addition, the liposomes could accumulate in tumor by passive targeting, thus facilitating the anti-tumor effects. Conclusion: The study provided new ideas for the development and clinical application of Bufonis venenum related formulation and offered new drug for the treatment of HCC.

Indexed as

Bufonis venenumcell apoptosishepatocellular carcinomaliposomestraditional Chinese medicine

Identifiers

PMID39654615
PMCPMC11625546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.